Works matching IS 17762596 AND DT 2023 AND VI 18 AND IP 2

Results: 12

FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer.

Published in:

Targeted Oncology, 2023, v. 18, n. 2, p. 269, doi. 10.1007/s11523-023-00949-7

By:

Caligiuri, Maureen;
Williams, Grace L.;
Castro, Jennifer;
Battalagine, Linda;
Wilker, Erik;
Yao, Lili;
Schiller, Shawn;
Toms, Angela;
Li, Ping;
Pardo, Eneida;
Graves, Bradford;
Azofeifa, Joey;
Chicas, Agustin;
Herbertz, Torsten;
Lai, Maria;
Basken, Joel;
Wood, Kenneth W.;
Xu, Qunli;
Guichard, Sylvie M.

Publication type:

Article

Comparison of Outcomes Between Therapeutic Combinations Based on Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitor Monotherapy for First-Line Therapy of Patients with Advanced Renal Cell Carcinoma Outside of Clinical Trials: A Real-World Retrospective Multi-Institutional Study

Published in:

Targeted Oncology, 2023, v. 18, n. 2, p. 209, doi. 10.1007/s11523-023-00956-8

By:

Ishihara, Hiroki;
Nemoto, Yuki;
Nakamura, Kazutaka;
Tachibana, Hidekazu;
Ikeda, Takashi;
Fukuda, Hironori;
Yoshida, Kazuhiko;
Kobayashi, Hirohito;
Iizuka, Junpei;
Shimmura, Hiroaki;
Hashimoto, Yasunobu;
Kondo, Tsunenori;
Takagi, Toshio

Publication type:

Article

Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?

Published in:

Targeted Oncology, 2023, v. 18, n. 2, p. 221, doi. 10.1007/s11523-023-00953-x

By:

Rimini, Margherita;
Persano, Mara;
Tada, Toshifumi;
Suda, Goki;
Shimose, Shigeo;
Kudo, Masatoshi;
Cheon, Jaekyung;
Finkelmeier, Fabian;
Lim, Ho Yeong;
Presa, José;
Masi, Gianluca;
Yoo, Changhoon;
Lonardi, Sara;
Piscaglia, Fabio;
Kumada, Takashi;
Sakamoto, Naoya;
Iwamoto, Hideki;
Aoki, Tomoko;
Chon, Hong Jae;
Himmelsbach, Vera

Publication type:

Article

Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma.

Published in:

Targeted Oncology, 2023, v. 18, n. 2, p. 235, doi. 10.1007/s11523-023-00954-w

By:

Piejko, Karolina;
Cybulska-Stopa, Bożena;
Ziętek, Marcin;
Dziura, Robert;
Galus, Łukasz;
Kempa-Kamińska, Natasza;
Ziółkowska, Barbara;
Rutkowska, Ewa;
Kopciński, Tomasz;
Kubiatowski, Tomasz;
Bal, Wiesław;
Suwiński, Rafał;
Mackiewicz, Jacek;
Kamińska-Winciorek, Grażyna;
Czarnecka, Anna M.;
Rutkowski, Piotr

Publication type:

Article

Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich<sup>LMU</sup> Molecular Tumor Board.

Published in:

Targeted Oncology, 2023, v. 18, n. 2, p. 257, doi. 10.1007/s11523-023-00950-0

By:

Dorman, Klara;
Zhang, Danmei;
Heinrich, Kathrin;
Reeh, Laurens;
Weiss, Lena;
Haas, Michael;
Beyer, Georg;
Rössler, Daniel;
Goni, Elisabetta;
Renz, Bernhard W.;
D'Haese, Jan G.;
Kunz, Wolfgang G.;
Seidensticker, Max;
Corradini, Stefanie;
Niyazi, Maximilian;
Ormanns, Steffen;
Kumbrink, Jörg;
Jung, Andreas;
Klauschen, Frederick;
Werner, Jens

Publication type:

Article

Analysis of Anti-Angiogenesis-Related Adverse Events Associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors (VEGFR-TKIs) in Patients with Metastatic Renal Cell Carcinoma.

Published in:

Targeted Oncology, 2023, v. 18, n. 2, p. 247, doi. 10.1007/s11523-023-00951-z

By:

Lee, Nuri;
Lee, Jae Lyun;
Lee, Ju-Yeun

Publication type:

Article

Abemaciclib: A Review in Early Breast Cancer with a High Risk of Recurrence.

Published in:

Targeted Oncology, 2023, v. 18, n. 2, p. 287, doi. 10.1007/s11523-023-00952-y

By:

Fung, Simon;
Blair, Hannah A.

Publication type:

Article

First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors.

Published in:

Targeted Oncology, 2023, v. 18, n. 2, p. 181, doi. 10.1007/s11523-023-00948-8

By:

Harding, James J.;
Jungels, Christiane;
Machiels, Jean-Pascal;
Smith, David C.;
Walker, Chris;
Ji, Tao;
Jiang, Ping;
Li, Xin;
Asatiani, Ekaterine;
Van Cutsem, Eric;
Abou-Alfa, Ghassan K.

Publication type:

Article

Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies.

Published in:

2023

By:

Popat, Sanjay;
Ahn, Myung-Ju;
Ekman, Simon;
Leighl, Natasha B.;
Ramalingam, Suresh S.;
Reungwetwattana, Thanyanan;
Siva, Shankar;
Tsuboi, Masahiro;
Wu, Yi-Long;
Yang, James Chih-Hsin

Publication type:

Correction Notice

Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan.

Published in:

Targeted Oncology, 2023, v. 18, n. 2, p. 195, doi. 10.1007/s11523-023-00946-w

By:

Hsu, Ping-Chih;
Lee, Suey-Haur;
Chiu, Li-Chung;
Lee, Chung-Shu;
Wu, Chiao-En;
Kuo, Scott Chih-Hsi;
Ju, Jia-Shiuan;
Huang, Allen Chung-Cheng;
Li, Shih-Hong;
Ko, Ho-Wen;
Yang, Cheng-Ta;
Wang, Chin-Chou

Publication type:

Article

Selinexor–Bortezomib–Dexamethasone: A Review in Previously Treated Multiple Myeloma.

Published in:

Targeted Oncology, 2023, v. 18, n. 2, p. 303, doi. 10.1007/s11523-022-00945-3

By:

Syed, Yahiya Y.

Publication type:

Article

Relugolix: A Review in Advanced Prostate Cancer.

Published in:

Targeted Oncology, 2023, v. 18, n. 2, p. 295, doi. 10.1007/s11523-022-00944-4

By:

Shirley, Matt

Publication type:

Article